PACIFIC BIOSCIENCES OF CALIF
PACBNASDAQTrading Snapshot
- Day Range
- $276.04 β $281.62
- 52-Week Range
- $1.07 β $2.73
- Volume
- $2.70B
- Avg Volume
- $2.99B
- Shares Outstanding
- 310.6M
- Next Earnings
- Dec 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $160M
- Last Q Revenue
- $39M
- P/E Ratio
- -3.8
- P/S Ratio
- 3.2x
- EPS (TTM)
- $-0.42
- Dividend Yield
- 0.00%
- Dilution (1yr)
- β1.6%
Why Investors Own PACB
- βHigh-growth profile β revenue up +51.6% YoY with expanding US Equity exposure.
- βHealthy economics β 29% gross margin and 28% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PACIFIC BIOSCIENCES OF CALIF
PACBAbout PACIFIC BIOSCIENCES OF CALIF
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
PACIFIC BIOSCIENCES OF CALIF tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift PACB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
PACIFIC BIOSCIENCES OF CALIF announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.